Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 378

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1C
Chunk 378
---
 paid in capital  105,998,412   97,583,906 Stock payable  -   5,233 Accumulated deficit  (103,438,099)  (91,930,152)Total Stockholders’ Equity  2,560,366   5,658,989 Total Liabilities and Stockholders’ Equity $4,452,362  $6,754,146 

The accompanying notes are an integral part of these consolidated financial statements.

 F-2 

ENDRA Life Sciences Inc.

Consolidated Statements of Operations

  Year Ended  Year Ended   December 31,   December 31,    2024  2023 Operating Expenses      Research and development $3,190,293  $5,003,695 Sales and marketing  571,040   820,554 General and administrative  7,055,814   4,696,486 Total operating expenses  10,817,147   10,520,735          Operating loss  (10,817,147)  (10,520,735)         Other (expenses) income        Other income  108,484   460,485 Warrant expense  (7,323,685)    Changes in fair value of warrant liability  3,447,737     Gain on settlement of warrant exercise  3,076,664     Total other expenses  (690,800)  460,485          Loss from operations before income taxes  (11,507,947)  (10,060,250)         Provision for income taxes  -   -          Net Loss $(11,507,947) $(10,060,250)         Net loss per share – basic and diluted $(56.94) $(2,766.85)         Weighted average common shares – basic and diluted  202,106   3,636 

The accompanying notes are an integral part of these consolidated financial statements.

 F-3 

ENDRA Life Sciences Inc.

Consolidated Statements of Stockholders’ Equity

Year Ended December 31, 2023  Series A Convertible  Series B Convertible             Total    Preferred Stock